

**Amendments to the Claims:**

**This listing of claims will replace all prior versions and listings of claims in the application.**

**Without prejudice or disclaimer, please cancel claims 1 to 15, 20 to 22, and 27 to 30.**

**Please amend claims 16 to 19, 23 to 26 and add new claims 31 to 46.**

1 to 15. (Canceled)

16. (Currently Amended) A method for inhibiting fusion between a membrane of a paramyxovirus and a plasma membrane of a cell comprising administering to a subject in need thereof a composition ~~according to claim 11~~ comprising an effective amount of at least one polypeptide sequence of SEQ ID NO: 1 or SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

17. (Currently Amended) The method of claim 16, wherein said paramyxovirus is of the genus *Henipavirus*.

18. (Currently Amended) The method of claim 16, wherein said paramyxovirus is of the subfamily *Paramyxovirina*.

19. (Currently Amended) The method of claim 16, wherein said virus is HeV or NiV.

20 to 22. (Canceled)

23. (Currently Amended) A method for treating infection with a virus, comprising administering ~~the a~~ composition comprising an effective amount of at least one polypeptide sequence of SEQ ID NO: 1 or SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

24. (Currently Amended) The method of claim 23, wherein said virus is a paramyxovirus.

25. (Currently Amended) The method of claim 23, wherein said paramyxovirus is of the genus *Henipavirus*.

26. (Currently Amended) The method of claim 23, wherein said virus is HeV or NiV.

27 to 30. (Canceled)

31. (New) A method for treating or preventing infection by a paramyxovirus, comprising administering to a subject in need thereof a pharmaceutically effective amount of a composition comprising at least one polypeptide selected from the group consisting of:
  - (a) a polypeptide comprising SEQ ID NO: 1; and
  - (b) a polypeptide comprising SEQ ID NO: 2.
32. (New) The method of claim 31, wherein the method comprises administering a polypeptide comprising SEQ ID NO: 1.
33. (New) The method of claim 31, wherein the method comprises administering a polypeptide comprising SEQ ID NO: 2.
34. (New) The method of claim 31, wherein the method comprises administering a polypeptide consisting of SEQ ID NO: 1.
35. (New) The method of claim 31, wherein the method comprises administering a polypeptide consisting of SEQ ID NO: 2.
36. (New) The method of claim 31, wherein the subject is human.
37. (New) The method of claim 31, wherein the composition further comprises a pharmaceutically acceptable carrier.
38. (New) The method of claim 37, wherein the composition is formulated for oral administration, subcutaneous injection, intravenous injection, intramuscular injection, or intraperitoneal injection.
39. (New) The method of claim 31, wherein the composition is formulated as a vaccine.
40. (New) The method of claim 31, wherein said paramyxovirus is of the genus *Henipavirus*.
41. (New) The method of claim 31, wherein said paramyxovirus is of the subfamily *Paramyxovirina*.
42. (New) The method of claim 31, wherein said virus is HeV or NiV.
43. (New) The method of claim 31, wherein the polypeptide comprises at least one second polypeptide.

44. (New) The method of claim 31, wherein the polypeptide is a fusion protein.
45. (New) The method of claim 31, wherein the method comprises administering a composition comprising a polypeptide comprising SEQ ID NO: 1 and a polypeptide comprising SEQ ID NO: 2.
46. (New) The method of claim 31, wherein the polypeptide comprises SEQ ID NO: 1 and SEQ ID NO: 2.